ADVANCING CAR-NK CELL THERAPY: OVERCOMING CHALLENGES IN MYELOID MALIGNANCIES

CAR-T has transformed blood cancers — but pancreatic, ovarian, and resistant myeloid tumors still win. What's next?

Cytokine storms. Neurotoxicity. GVHD. The barriers to safe, effective immunotherapy in hard-to-treat malignancies are well known — the solutions less so. Two pioneers share what's working in their labs right now.

Advancing CAR‑NK Cell Therapy for Refractory Myeloid and Solid Tumors

Despite major strides with CAR‑T cells, researchers continue to face limited efficacy and significant toxicity challenges in myeloid and solid malignancies.

What You'll Learn
Discover emerging CAR‑NK strategies that address these barriers—from cytokine‑activated and armored NK cells to CRISPR‑guided engineering of next‑generation CAR‑NK therapies. Hear new data on NK‑based immunotherapy for pancreatic, ovarian, and other difficult‑to‑treat cancers, plus a novel approach using engineered gut‑derived bacteria to drive anti‑tumor immunity.

Key Takeaways
• How NK and CAR‑NK platforms reduce CRS, neurotoxicity, and GVHD
• Advances in armored and cytokine‑activated NK cell designs
• CRISPR‑enabled discovery for overcoming resistance in solid tumors
• Novel microbial‑based biologic delivery for immune activation

Who Should Attend
Researchers and scientists developing or evaluating advanced NK‑cell and adoptive cell therapy platforms.

Translational researchers, immunologists, hematology and oncology scientists, cell therapy investigators, and clinician-scientists with an interest in adoptive cell therapy, NK cell biology, CRISPR-based engineering, or tumor microenvironment reprogramming. 

Save Your Spot
Join us to explore next‑generation strategies reshaping CAR‑NK therapy for hard‑to‑treat cancers.

The views and opinions expressed by the invited speakers are their own and do not necessarily reflect the views or positions of the AACR.